Inhibition of matrix metalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia.
Persistent arterial hypotension is a hallmark of sepsis and is believed to be caused, at least in part, by excess nitric oxide (NO). NO can combine with superoxide to produce peroxynitrite, which activates matrix metalloproteinases (MMPs). Whether MMP inhibition in vivo protects against vascular hyporeactivity induced by endotoxemia is unknown. Male Sprague-Dawley rats were administered either bacterial lipopolysaccharide (LPS, 4 mg/kg ip) or vehicle (pyrogen-free water). Later (30 min), animals received the MMP inhibitor doxycycline (4 mg/kg ip) or vehicle (pyrogen-free water). After LPS injection (6 h), animals were killed, and aortas were excised. Aortic rings were mounted in organ baths, and contractile responses to phenylephrine or KCl were measured. Aortas and plasma were examined for MMP activity by gelatin zymography. Aortic MMP and inducible nitric oxide synthase (iNOS) were examined by immunoblot and/or immunohistochemistry. Doxycycline prevented the LPS-induced development of ex vivo vascular hyporeactivity to phenylephrine and KCl. iNOS protein was significantly upregulated in aortic homogenates from endotoxemic rats; doxycycline did not alter its level. MMP-9 activity was undetectable in aortic homogenates from LPS-treated rats but significantly upregulated in the plasma; this was attenuated by doxycycline. Plasma MMP-2 activities were unchanged by LPS. Specific MMP-2 activity was increased in aortas from LPS-treated rats. This study demonstrates the in vivo protective effect of the MMP inhibitor doxycycline against the development of vascular hyporeactivity in endotoxemic rats.
Cena
Jonathan J
JJ
Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada.
Lalu
Manoj M
MM
Cho
Woo Jung
WJ
Chow
Ava K
AK
Bagdan
Mariel L
ML
Daniel
Edwin E
EE
Castro
Michele M
MM
Schulz
Richard
R
D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects; D001808:Blood Vessels / Q000503:physiopathology; D015153:Blotting, Western; D004318:Doxycycline / Q000627:therapeutic use*; D019446:Endotoxemia / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology*; D005780:Gelatin / Q000378:metabolism; D066298:In Vitro Techniques; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism; D018613:Microscopy, Confocal; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D010656:Phenylephrine / Q000494:pharmacology; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011506:Proteins / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D008070:Lipopolysaccharides; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D011506:Proteins; D014662:Vasoconstrictor Agents; D010656:Phenylephrine; D005780:Gelatin; D052247:Nitric Oxide Synthase Type II; D020782:Matrix Metalloproteinases; D020780:Matrix Metalloproteinase 9; D004318:Doxycycline